ClinicalTrials.gg
RecruitingNCT06533332Updated May 29, 2026

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of ERX-315 in Advanced Solid Tumor, Metastatic Breast Cancer and Metastatic Ovarian Cancer, sponsored by EtiraRx Australia Pty Ltd. Recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Primary conditionnone(registry's first term: Breast Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Breast Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by EtiraRx Australia Pty Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Read the detailed description

The goal of this open-label, dose escalation and cohort expansion Phase 1 clinical trial is to determine the safety, tolerability and pharmacokinetics of ERX-315 in patients with advanced solid tumors, who have progressed on prior approved systemic therapies. Participants will receive ERX-315 as an intravenous (IV) injection twice a week, over 21-day cycles.

02

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Breast Cancer
  • Metastatic Ovarian Cancer
  • Metastatic Endometrial Cancer
  • Metastatic Liver Cancer
  • Metastatic Pancreatic Cancer
03

In context

Lead sponsor

This is the only study on the registry with EtiraRx Australia Pty Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be at least 18 years of age at the time of signing the .
  • (ECOG) performance status 0 or 1.
  • Patients must have or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial and hepatocellular carcinoma, that is advanced unresectable and/or disease for whom standard therapies do not exist or are no longer effective
  • Patients must have as per (RECIST) v1.1.
  • Adequate baseline organ function and hematologic function
  • >3 months

Exclusion criteria

Exclusion Criteria:

  • Systemic anti cancer therapy within 4 weeks of first dose of study drug
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Uncontrolled intercurrent illnesses
  • Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    ERX-315

    Active investigational therapy

    Drug: ERX-315

Interventions

  • DrugERX-315

    Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities of ERX-315

    First cycle dose limiting toxicities characterized by type, frequency, severity, timing, seriousness, and relationship to study drug

    Time frame: 21 days

  2. Incidence of Adverse Events as a measure of safety and tolerability of ERX-315

    Adverse events as characterized by type, frequency, severity (grade), timing, seriousness, and relationship to study drug.

    Time frame: 84 days

  3. Incidence of laboratory abnormalities as a measure of safety and tolerability of ERX-315

    Laboratory abnormalities as characterized by type, frequency, severity, and timing.

    Time frame: 84 days

  4. Determination of the recommended phase 2 dose

    To determine the recommended phase 2 dose(s) for additional evaluation of ERX-315 in clinical trials for participants with advanced solid tumors

    Time frame: 84 days

Secondary outcomes

  1. Assessment of pharmacokinetic outcome measure of Area under the plasma concentration versus time curve (AUC).

    AUC will be determined by non-compartmental analysis and assessed after single and multiple doses of drug

    Time frame: 21 days

  2. Assessment of pharmacokinetic outcome measure of Peak Plasma concentration (Cmax)

    Cmax will be determined by non-compartmental analysis and assessed after single and multiple doses of drug

    Time frame: 21 days

  3. Assessment of pharmacokinetic outcome measure of drug half-life (t1/2)

    t1/2 will be assessed after single and multiple doses of drug

    Time frame: 21 days

  4. Antitumor activity of ERX-315 based on Objective response rate (ORR)

    ORR will be assessed by RECIST v1.1

    Time frame: 84 days

  5. Antitumor activity of ERX-315 based on Best Overall Clinical Response (BOCR)

    BOCR will be assessed by RECIST v1.1

    Time frame: 84 days

  6. Antitumor activity of ERX-315 based on Duration of response (DOR)

    DOR will be assessed by RECIST v1.1 and time frame of response

    Time frame: 84 days

  7. Antitumor activity of ERX-315 based on Progression-free survival (PFS)

    PFS will be assessed by RECIST v1.1 and time frame of response

    Time frame: 84 days

Other outcomes

  1. Impact on patient reported symptoms using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire

    Effect of ERX-315 on the changes from baseline in patient reported symptoms using the PRO-CTCAE Questionnaire

    Time frame: 84 days

  2. Serum LIPA lipase activity as pharmacodynamic markers of ERX-315 activity

    The effect of ERX-315 on serum LIPA lipase activity may be evaluated

    Time frame: 84 days

  3. Circulating tumor DNA levels as pharmacodynamic markers of ERX-315 activity

    The effect of ERX-315 on circulating tumor DNA levels may be evaluated

    Time frame: 84 days

07

Study locations

5 of 5 sites recruiting
  • Macquarie University Health
    Ryde, New South Wales 2109, Australia
    Recruiting
    • · Contactreception@muh.org.au · +61 (2) 9812 3000
    • Danusha Sabanathan, FRACP PhD · Principal investigator
  • The Kinghorn Cancer Center
    Sydney, New South Wales 2010, Australia
    Recruiting
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Jeremy Mo, MD · Contact(02) 8890 6666
    • Jeremy Mo, MD · Principal investigator
  • Cancer Research SA
    Adelaide, South Australia 5000, Australia
    Recruiting
    • Kelly Mead · Contactadmin@crsa.au · 08 8359 2565
    • Rohit Joshi, MBBS, FRACP · Principal investigator
  • Icon Cancer Centre Adelaide
    Adelaide, South Australia 5037, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2024
First posted
Aug 1, 2024
StartActual
Oct 14, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 30, 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06533332
Lead sponsor
EtiraRx Australia Pty Ltd
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Oct 14, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 29, 2026

Study contacts

Research Director
Contact
contact@etira.life
01 469 600 6603
Rasha Cosman, MBBS
principal investigator · The Kinghorn Cancer Centre

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion